sanjeri/E+ via Getty Images
SpringWorks Therapeutics (NASDAQ:SWTX) may be valued at about $77 a share in a possible takeover after a report earlier that Merck KGaA (OTCPK:MKGAF) is in talks for a purchase of the cancer and rare disease drugmaker, according to